SequelSEC

Acumen Pharmaceuticals, Inc. ABOS

Biological Products, (No Diagnostic Substances) · CIK 0001576885 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$105.42M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Acumen Pharmaceuticals, Inc. (ABOS) reported net income of -$105.04M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Acumen Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Acumen Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
RevenueUnavailable
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$105.42M
Net income-$105.04M
Research & development$86.79M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$18.63M
Selling & marketingUnavailable

Balance

Acumen Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$59.44M
Total assets$116.01M
Current assets$115.51M
Total liabilities$58.74M
Current liabilities$46.85M
Total equity incl. NCI$57.26M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debt$11.90M
Accounts payable$13.38M

Cash flow

Acumen Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$91.79M
Capital expendituresUnavailable
Investing cash flow$78.95M
Financing cash flow$35.47M
Net change in cashUnavailable
Stock-based compensation$9.80M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Acumen Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio2.47x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equity0.21x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ABOS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO AMGN

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.